文献速递乳腺MR

多模态跨时序融合系统辅助评估乳腺癌新辅助化疗

A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer.
PubMed 文献 · Eur J Radiol · 2026-09-09

基于1515例局部晚期乳腺癌患者新辅助化疗前后DCE-MRI及临床资料,开发多模态自动新辅助化疗辅助系统MANAS。该系统含三个模块,分别用于预测分子亚型、新辅助化疗反应及残余肿瘤负荷。

要点

  • MANAS可提供从初始诊断到手术干预的全流程纵向支持证据
  • 系统预测分子亚型、化疗反应及残余肿瘤负荷的AUC均超过0.77
  • 置信度决策标准可将低置信度病例交由临床医生处理并提升性能

核心结论

  • MANAS可作为有价值的补充工具,在新辅助化疗全程中提供纵向支持证据,覆盖从初始诊断到手术干预的各阶段

研究设计与样本

  • 研究开发多模态自动新辅助化疗辅助系统MANAS,采用双通路注意力多尺度特征融合框架
  • 使用多中心数据集,纳入1515例局部晚期乳腺癌患者新辅助化疗前后DCE-MRI及关联临床信息
  • 以内部测试集、汇总外部测试集及I-SPY2测试集评估系统性能

关键影像表现/征象

  • 系统融合新辅助化疗前后纵向跨时序DCE-MRI与临床数据进行预测
  • MANAS包含从乳腺癌诊断到后续治疗的三个模块,分别针对分子亚型、新辅助化疗反应及残余肿瘤负荷

诊断标准与关键数值

  • 分子亚型预测:内部测试集AUC为0.8066(95%CI 0.7552-0.8599),汇总外部测试集AUC为0.7748(95%CI 0.7210-0.8275),I-SPY2测试集AUC为0.7661(95%CI 0.6980-0.8252)
  • 新辅助化疗反应预测:内部测试集AUC为0.8400(95%CI 0.7903-0.8896),汇总外部测试集AUC为0.8299(95%CI 0.7886-0.8687)
  • 残余肿瘤负荷预测:内部测试集AUC为0.8885(95%CI 0.7891-0.9657),汇总外部测试集AUC为0.8628(95%CI 0.8047-0.9132),I-SPY2测试集AUC为0.8695(95%CI 0.7856-0.9432)
  • 置信度决策标准用于将低置信度病例转交临床医生,并可增强预测性能

临床应用与阅片要点

  • 放射科医生可借助该系统在乳腺癌新辅助化疗前后对照DCE-MRI时获得分子亚型、疗效及残余肿瘤负荷的辅助预测
  • 对系统低置信度输出的病例应转由临床医生进一步评估,不宜单独作为决策依据

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Neoadjuvant chemotherapy (NAC) has been established as a standard treatment for breast cancer. We aimed to develop a deep-learning multimodal system using longitudinal cross-temporal dynamic contrast-enhanced MRI (DCE-MRI) and clinical data to provide complementary evaluation of NAC.

METHODS: Here, we developed a multimodal automatic NAC assistance system (MANAS), which leverages a dual-pathway attention-based multi-scale feature fusion framework and a multicenter dataset. This dataset comprises pre- and post-NAC DCE-MRI and associated clinical information of 1,515 patients with locally advanced breast cancer. The performance of MANAS was evaluated using various metrics. Confidence-based decision criteria were employed to defer low-confidence cases to clinicians.

RESULTS: MANAS consisted of three modules from breast cancer diagnosis to follow-up treatment, designed for predicting molecular subtype, NAC response, and residual tumor burden, respectively. MANAS achieved area under the curves (AUCs) of 0.8066 (95 % CI: 0.7552-0.8599), 0.7748 (95 % CI: 0.7210-0.8275) and 0.7661 (95 % CI: 0.6980-0.8252) on the internal, pooled external and I-SPY2 test sets for molecular subtype prediction; AUCs of 0.8400 (95 % CI: 0.7903-0.8896) and 0.8299 (95 % CI: 0.7886-0.8687) on the internal and pooled external test sets for NAC response prediction; and AUCs of 0.8885 (95 % CI: 0.7891-0.9657), 0.8628 (95 % CI: 0.8047-0.9132) and 0.8695 (95 % CI: 0.7856-0.9432) on the internal, pooled external and I-SPY2 test sets for residual tumor burden prediction. Confidence-based decision criteria could enhance their predictive performance.

CONCLUSION: Our MANAS serves as a valuable complementary tool, providing longitudinal supportive evidence throughout the NAC process, from initial diagnosis to surgical intervention.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Sun, Wang, Zhou, et al. A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer. Eur J Radiol. 2026. PMID: 42753332. doi:10.1016/j.ejrad.2026.113214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。